• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom

Dexcom receives FDA warning letter

March 7, 2025 By Sean Whooley

Dexcom updated Logo

Dexcom (Nadsaq:DXCM) announced today that it received a warning letter from the FDA following inspections of two company facilities. The letter followed inspections of the company’s plants in San Diego and Mesa, Arizona. San Diego is where Dexcom’s headquarters is located, while the company last year decided to move manufacturing out of San Diego to […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Technology Tagged With: Dexcom, FDA

Data outlines need for CGM study design guidelines

February 21, 2025 By Sean Whooley

Medtronic Simplera Abbott FreeStyle Libre 3 Dexcom G7

A study looking at three leading continuous glucose monitors (CGMs), including systems from Abbott and Dexcom, signaled the need for new guidelines, investigators say. Published in the Journal of Diabetes Science and Technology, the study evaluated the latest-generation Abbott FreeStyle Libre 3, Dexcom G7 and Medtronic Simplera CGMs against different comparator methods and during clinically […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, Dexcom, Medtronic

Dexcom posts Q4 EPS miss, analysts remain high on coming catalysts

February 14, 2025 By Sean Whooley

Dexcom updated Logo

Dexcom (Nadsaq:DXCM) announced fourth-quarter results that came in mixed compared to the consensus forecast — but analysts are optimistic about 2025. Shares of DXCM initially fell after-hours yesterday on the after-market-close report — but by midday today, they were up more than 5% to $89.03 apiece. The San Diego-based continuous glucose monitor (CGM) maker reported […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Dexcom

Dexcom warns of missed G6 receiver alerts in Europe

February 10, 2025 By Sean Whooley

Dexcom urgent field safety notice G6 receiver

Dexcom (Nasdaq:DXCM) recently issued an urgent field safety notice in Europe warning of a potential issue with certain G6 receivers. G6 continuous glucose monitor (CGM) receivers deliver glucose readings and alerts. However, certain devices may experience an issue in which alarms/alerts fail to function as designed. In rare instances, the alarm/alert may be missed or […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Recalls, Regulatory/Compliance, Technology Tagged With: Dexcom

Dexcom establishes direct presence in Italy with CGM launch, ends distro deal with Roche

February 5, 2025 By Sean Whooley

Dexcom One+ real-time continuous glucose monitor CGM system

Dexcom (Nasdaq:DXCM) announced today that it plans to establish a direct presence in Italy, bringing its CGM technology to the country. The company plans to bring its continuous glucose monitoring (CGM) technology to Italy beginning in March 2025. This means it plans to end its distribution relationship with Roche next month. The companies plan to […]

Filed Under: Business/Financial News, Diabetes, Distribution, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Dexcom

Are over-the-counter CGMs on track to be one-hit wonders?

February 5, 2025 By drugdelivery

Steph-Habif-Stelo

This medical device design expert’s family conducted a group trial of Dexcom Stelo and Abbott Lingo CGMs. By Steph Habif “Did you say you are now wearing a CGM?” my 78-year-old father asked me one day. “If so, what brand do you think is best for me to try?” My dad wanted my opinion because […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, CGM, Dexcom

Dexcom CEO says 2025 is ‘shaping up to be a good year’ with Stelo launch, GenAI integration

January 23, 2025 By Sean Whooley

Stelo glucose sensor by Dexcom Phone (1) diabetes

After a busy 2024, Dexcom (Nasdaq:DXCM) Chair and CEO Kevin Sayer believes the company is set for more milestones in 2025. In 2024, the company became the first to receive FDA approval for an over-the-counter (OTC) continuous glucose monitor (CGM), the Stelo device. Meanwhile, Dexcom continues to advance its G7 platform, its latest-generation CGM offering. […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Dexcom, Oura

Dexcom inks glucose biosensor partnership with Life Time

January 18, 2025 By Sean Whooley

Dexcom Stelo worn by pickleball player

Dexcom (Nasdaq:DXCM) announced that it entered into a new partnership with Life Time Inc., an operator of athletic country clubs. Life Time Inc., a “health and wellness pioneer,” has more than 170 athletic country clubs across the U.S. The chain of clubs also extends into Canada. In a post on LinkedIn, Dexcom said it announced […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Dexcom

Dexcom expects sales to grow 14% in 2025

January 13, 2025 By Sean Whooley

Dexcom updated Logo

Dexcom (Nasdaq:DXCM) today announced preliminary financial results with projections for significant sales growth in 2025. Shares of DXCM dipped 1.5% to $76.57 in mid-morning trading today. The San Diego-based continuous glucose monitor (CGM) maker reported preliminary 2024 revenues of $4.032 billion. That marks an 11% increase over 2023. For 2025, Dexcom anticipates total revenue of […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Dexcom

Abbott, Dexcom settle global CGM patent litigation

December 23, 2024 By Sean Whooley

Dexcom G7 Abbott FreeStyle Libre 2 CGM

Abbott (NYSE:ABT) announced today that it reached an agreement with Dexcom (Nasdaq:DXCM) to settle all outstanding patent disputes between companies. The patent litigation relates to the companies’ continuous glucose monitor (CGM) technologies. Abbott and Dexcom are two leaders in the CGM space. They offer market-leading platforms, with Abbott’s FreeStyle Libre 3 and Dexcom’s G7 representing […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Legal News, Patient Monitoring, Regulatory/Compliance Tagged With: abbott, Dexcom

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 17
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS